Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.30 |
| ▸ | STS | P08842 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710400 | 0.88 | GRM5 (0.31) | — | |
| SCHEMBL4706196 | 0.87 | ALDH1A1 (0.33) | MEN1KMT2ASTS | |
| SCHEMBL4189478 | 0.79 | GPR119 (0.35) | — | |
| SCHEMBL4189483 | 0.79 | GPR119 (0.35) | — | |
| SCHEMBL4189470 | 0.79 | GPR119 (0.35) | — | |
| SCHEMBL4180237 | 0.78 | GPR119 (0.36) | — | |
| SCHEMBL4180242 | 0.78 | GPR119 (0.36) | — | |
| SCHEMBL4180233 | 0.78 | GPR119 (0.36) | — | |
| SCHEMBL7772596 | 0.78 | ELANE (0.46) | — | |
| SCHEMBL2447629 | 0.76 | GRM5 (0.37) | CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1221445-B1 | PENTACYCLIC TAXANE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-6677456-B2 | AS ANTITUMOR COMPOUND; CAN BE ORALLY ADMINISTERED | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20020143178-A1 | Pentacyclic taxan compound | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-10-03 | — | — | US | disclosed |
| EP-1221445-A1 | PENTACYCLIC TAXANE COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143178-A1 | Pentacyclic taxan compound | TUBB6, TUBB1, TUBA1A | TRPA1 3740/4885TP53 70/4885MDM2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.